ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer#882025
- Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide#1410740
- Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer#1439435
- Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"#1438965
- A Study of Degarelix in Patients With Prostate Cancer#1073142
Record · ID 1438917
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive